Pfizer's Lipitor share slips, casting doubt on power of a loyalty program to save the brand

Share this article:
Study anticipates higher statin use
Study anticipates higher statin use
Seven weeks after Pfizer's main Lipitor patent expired in the US, the drug is down to 32% market share and at least one name-brand analyst is casting doubt on the brand's survival strategy.

“While this is not the first time that pharma companies have tried (unsuccessfully) to strike post-generic deals with payors, Pfizer's attempts appear to be more aggressive and could set forth a new precedent if successful,” wrote Goldman Sachs analyst Jami Rubin in a Monday analyst note. “However, according to IMS data, Pfizer's share may be starting to slip.”

“Recall,” she added, “that Watson's guidance assumes Pfizer's strategy allows it to retain a 40% market share, and WPI and RBXY split the generic market.”

In fact, Pfizer's share of the market dipped below 40% two weeks after exclusivity loss, languishing at 37% for several weeks before dropping further in recent days.

Pfizer awarded Watson Pharmaceuticals rights on an authorized generic, and that company's CEO, Paul Bisaro, said Pfizer's Lipitor endgame isn't working.

“They're starting to lose market share,” said Bisaro in an analyst meeting, according to Bloomberg. “It appeared they were trying to protect revenue and not profit.”

Watson boasts 27% of the atorvastatin market, according to the IMS numbers, though Bisaro has suggested that IMS undercounts its sales of the drug through Walmart. An unauthorized rival generic by Ranbaxy was in the lead, with 41% share.

Asked about Bisaro's comments, a Pfizer spokesperson said the company's Lipitor For You loyalty program would differentiate the Pfizer product by “increasing patient choice and improving patient adherence by offering Lipitor patients more support than they would receive from a company selling generic atorvastatin,” including a $4 co-pay card, designed to lower patients' out of pocket costs to equal with or lower than the cost of a generic, as well as “counseling, education and adherence tools through expanded partnerships with participating pharmacies.”
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.